ClinicalTrials.gg
CompletedNCT07211165Updated Jan 16, 2026

Clinical Study on the Mass Balance of Clifutinib

A Phase 1 interventional study of [14C]Clifutinib in Healthy Adult Male, sponsored by Sunshine Lake Pharma Co., Ltd.. Completed at 1 site in China. Open to male participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-01-16.

Sponsored by Sunshine Lake Pharma Co., Ltd. · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
6
Allocation
Not applicable
Ages
18 Years to 45 Years
Sex
Male
01

Study summary

To investigate the plasma total radioactivity PK characteristics of male healthy subjects after a single oral administration of [14C]Clifutinib, the distribution of total radioactivity in whole blood and plasma, and to determine the main excretion and metabolic pathways.

02

Conditions studied

  • Healthy Adult Male

Keywords

  • Clifutinib
03

In context

Lead sponsor

Sunshine Lake Pharma Co., Ltd. is the lead sponsor of 83 studies on the registry; 13 are open to participants now.

Of its 6 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Healthy male, age: 18 - 45 years (inclusive of boundary values).
  2. Weight of no less than 50 kg, and (BMI) within the range of 19 kg/m2 - 26 kg/m2 (including critical values).
  3. Signed the form before the trial and fully understood the trial content, process and possible adverse reactions.
  4. The subjects can communicate well with the researchers and complete the trial in accordance with the protocol.

Exclusion criteria

Exclusion Criteria:

  1. Those with abnormal and findings in comprehensive physical examination, routine laboratory tests (blood routine, blood biochemistry, C-reactive protein, coagulation function, urine routine), stool routine + occult blood, thyroid function, 12-lead , chest CT, abdominal B-ultrasound (liver, gallbladder, pancreas, spleen, kidney), etc.
  2. Those who fail the vital sign examination and still fail after re-examination.
  3. Those with abnormal and clinically significant findings in ophthalmological examination (slit lamp, intraocular pressure, fundus photography).
  4. Those with abnormal and clinically significant findings in surface antigen, hepatitis B e antigen, anti- IgG, -Ag/Ab, and syphilis antibody tests, as determined by the investigator.
  5. Those who have used inhibitors or inducers within 30 days before the screening period, as detailed in Appendix 1.
  6. Those who have used any prescription drugs, over-the-counter drugs, herbal health products, or food supplements (such as vitamins, calcium supplements) within 14 days before the screening period.
  7. Those with a history of or current diseases in the musculoskeletal system, nervous and mental system, endocrine system, circulatory system, respiratory system, digestive system, urinary system, reproductive system, etc., and the investigator deems it clinically significant.
  8. Those with any diseases that increase the risk of elevated blood sugar, such as a history of primary diabetes, -induced diabetes, other secondary diabetes, acute or chronic pancreatitis, and the investigator deems it clinically significant.
  9. Those with a history of organic heart disease, heart failure, myocardial infarction, angina pectoris, unexplained arrhythmia, torsades de pointes, ventricular tachycardia, atrioventricular block, and the investigator deems it clinically significant; those with > 450ms during the screening period.
  10. Those with interstitial lung disease, severely impaired lung function, severe pulmonary fibrosis, radiation pneumonitis, drug-induced lung disease, and evidence of active pulmonary inflammation on chest CT during the screening period, and the investigator deems it clinically significant.
  11. Those who have undergone major surgery within 6 months before the screening period or whose surgical incisions have not fully healed; major surgeries include but are not limited to any surgeries with significant bleeding risk, prolonged general anesthesia, or incisional or obvious traumatic injury, or surgeries that affect drug absorption, distribution, metabolism, and excretion, or those planning to undergo surgery during the study period.
  12. Those with drug, environmental, food allergies or allergic constitution, or those the investigator deems may be allergic to the study drug or its .
  13. Those with hemorrhoids or perianal diseases with regular/ongoing bleeding, irritable bowel syndrome, inflammatory bowel disease.
  14. Those with multiple factors affecting oral and drug absorption (such as inability to swallow, post-gastrointestinal resection, ulcerative colitis, symptomatic/inflammatory bowel disease, and intestinal obstruction, etc.).
  15. Those with habitual constipation or diarrhea.
  16. Those with lactose intolerance (those who have experienced diarrhea after drinking milk).
  17. Those who are heavy drinkers or have frequently consumed alcohol within 6 months before the screening period (more than 14 units of alcohol per week, 1 unit = 360 mL of beer or 45 mL of 40% alcohol or 150 mL of wine), or those who cannot abstain from alcohol during the trial, or those with a breath alcohol test result > 0 mg/100 mL during the screening period.
  18. Those who smoke more than 5 cigarettes per day or habitually use nicotine-containing products within 3 months before the screening period and cannot quit during the trial.
  19. Those who have abused drugs or used soft drugs (such as marijuana) within 3 months before the screening period or hard drugs (such as cocaine, amphetamines, phencyclidine, etc.) within 1 year before the screening period, or those with positive urine drug tests during the screening period.
  20. Habitual consumption of grapefruit juice or excessive tea, coffee and/or caffeine-containing beverages, and those who are unable to abstain during the trial period.
  21. Workers exposed to radiation for long periods of time, or those who have had significant radiation exposure (≥2 chest/abdominal CTs or ≥3 other types of X-ray examinations) within one year prior to signing the ICF, or those who have participated in radiolabeled drug trials within one year prior to signing the ICF.
  22. Those with a history of fainting at the sight of needles or blood, or those who have difficulty with blood collection or cannot tolerate venipuncture.
  23. Those who have participated in other clinical trials and used other drugs or devices within three months before screening or during the screening period, or those who plan to participate in other clinical trials during this study, or those who are not the subjects themselves.
  24. Those who have received vaccinations within one month before screening or plan to receive vaccinations during the trial period.
  25. Those who have plans to conceive or donate sperm within one year from signing the ICF to one year after receiving the investigational drug, or those who do not agree that both the subject and their spouse should take strict measures during this period (see Appendix 3 for details).
  26. Those who have lost or donated blood of 400 mL or more within three months before the screening period, or those who have received blood transfusions within one month.
  27. Those who are considered unsuitable for participation in the trial by the investigator for other reasons, or those who withdraw from the trial for their own reasons.
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
6 participants (actual)

Study arms

  • Experimental
    [14C]Clifutinib

    On Day 1, subjects will receive a single oral dose of 40 mg/100 µCi \[14C\]Clifutinib

    Drug: [14C]Clifutinib

Interventions

  • The subjects are required to take the test drug on an empty stomach for at least 10 hours and without drinking water for 1 hour. After taking the drug, they should fast for 4 hours and refrain from drinking water for 1 hour.

06

What researchers measure

Primary outcomes

  1. AUC0-∞

    Investigate the plasma total radioactivity PK characteristics of male healthy subjects after a single oral administration of \[14C\] Clifutinib

    Time frame: From Day 1 of dosing to the Day 85 after dosing

  2. Tmax

    Investigate the plasma total radioactivity PK characteristics of male healthy subjects after a single oral administration of \[14C\] Clifutinib

    Time frame: From Day 1 of dosing to the Day 85 after dosing

  3. Cmax

    Investigate the plasma total radioactivity PK characteristics of male healthy subjects after a single oral administration of \[14C\] Clifutinib

    Time frame: From Day 1 of dosing to the Day 85 after dosing

  4. Percentage of metabolites in plasma relative to total exposure AUC (% AUC)

    Investigate the distribution of total radioactivity in plasma of male healthy subjects after a single oral administration of \[14C\] Clifutinib.

    Time frame: From Day 1 of dosing to the Day 85 after dosing

  5. The total radioactivity

    Quantitative analysis was conducted on the total radioactivity in the feces and urine of male health subjects after oral administration of \[14C\] Clifutinib, to obtain the data on human recovery rate and determine the main excretion pathway.

    Time frame: From Day 1 of dosing to the Day 85 after dosing

  6. Identification of major metabolites in plasma, urine, and fecal samples

    Obtain the radioactive metabolite profiles in plasma, urine and feces of male healthy subjects after oral administration of \[14C\]Clifutinib, identify the main metabolites, and determine the metabolic and elimination pathways.

    Time frame: From Day 1 of dosing to the Day 85 after dosing

Secondary outcomes

  1. AUC0-∞

    The validated liquid chromatography-tandem mass spectrometry (LC-MS/MS) method was used to quantitatively analyze the concentrations of Clifutinib, its metabolite (M3), and other metabolites (if applicable) in plasma, thereby obtaining the corresponding pharmacokinetic parameters.

    Time frame: From Day 1 of dosing to the Day 85 after dosing

  2. Tmax

    The validated liquid chromatography-tandem mass spectrometry (LC-MS/MS) method was used to quantitatively analyze the concentrations of Clifutinib, its metabolite (M3), and other metabolites (if applicable) in plasma, thereby obtaining the corresponding pharmacokinetic parameters.

    Time frame: From Day 1 of dosing to the Day 85 after dosing

  3. Cmax

    The validated liquid chromatography-tandem mass spectrometry (LC-MS/MS) method was used to quantitatively analyze the concentrations of Clifutinib, its metabolite (M3), and other metabolites (if applicable) in plasma, thereby obtaining the corresponding pharmacokinetic parameters.

    Time frame: From Day 1 of dosing to the Day 85 after dosing

  4. Frequency, type and severity of adverse events/serious adverse events; changes in vital signs, 12-lead ECGs, laboratory tests, etc.

    Observation of the safety profile in male healthy subjects after a single administration of \[14C\] Clifutinib

    Time frame: From Day 1 of dosing to the Day 85 after dosing

07

Study locations

1 site
  • Affiliated hospital of Jiangnan University
    Wuxi, Jiangsu 214000, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Sep 2025 to primary completion in Nov 2025, 1 month.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 22, 2025
First posted
Oct 7, 2025
StartActual
Sep 29, 2025
Primary completionActual
Nov 5, 2025
CompletionActual
Nov 12, 2025
Last update
Jan 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 16, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07211165
Responsible party
Sponsor
First posted
Oct 7, 2025
Start date
Sep 29, 2025
Primary completion
Nov 5, 2025
Completion
Nov 12, 2025
Last update
Jan 16, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Clifutinib

Start the discussion